Fritextsökning
Innehållstyper
-
Samuel Lagercrantz: ”Will the Swedish life science strategy be updated with precision?”
What will the Swedish government focus on in the life science strategy that is being updated? And what should be prioritized in the strategy? Life Science Swede...
-
FDA approves new cystic fibrosis therapy
A new treatment for cystic fibrosis has been approved by the U.S. Food and Drug Administration (FDA).
-
To build trust, one must be able to say “I don’t know” – whether human or AI
Will AI strengthen or break down trust? It depends on whether we can understand and accept its limitations, and our own, writes Sarah Lidé in a column.
-
How to transport hydrogen - the BionicHydrogenBattery
Have you ever wondered how hydrogen should be transported and stored safely. Well, here is a solution for all who is interested in making a true infrastructure work.
-
Meeting with focus on South Korea and Japan’s life sciences
Large, complex and exciting – this is how Britta Stenson, Business Sweden, describes the life science markets of Japan and South Korea, which took centre stage ...
-
”The importance of stratification in a statistician’s August kitchen”
Ingrid Lönnstedt writes about an experiment of her own at home and about what lessons can be learned from it, in a science column.
-
A small thing that can solve your problems
If you are in need of a compact valve. Look no further! We have the VOVK
-
Thumbs down for lecanemab in the EU – “Very surprised”
The Azheimer's drug lecanemab has received a negative assessment from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), acc...
-
GSK acquires oncology research company
GSK acquires the American biotechnology company Idrx for up to 1.15 billion dollars.
-
ZEISS Quality Innovation Days: April 15 – 19, 2024
Be there when industry experts give exciting insights into different applications and trends in 90 minutes on various theme days.
-
Conference recordings now available
Don't miss out on insights from leading experts.
-
Samuel Lagercrantz: “Companies that do this successfully will take the lead”
The development of new medicines and medical technologies should not focus too narrowly on prolonging life. It is equally important to develop treatments that r...
-
BioProTT Clamp-On SL beröringsfria flödesgivare
BioProTT Clamp-On SL beröringsfria flödesgivare för single-use bioprocessteknik – från PSG Biotech.
-
Gothenburg, the city of life science – We are ‘Little Boston’
Western Sweden is investing in life science within everything from advanced therapeutic drugs to femtech. At the same time, stakeholders are looking to other in...
-
FDA approves first non-opioid pain reliever in over 20 years
For the first time in decades, a new type of acute pain medication that is not an opioid has been approved in the USA.
-
ZEISS O-INSPECT duo: The multifunctional measuring machine
ZEISS O-INSPECT duo combines advanced microscopy and metrology for impressive measurement accuracy.
-
Reveal the Structures and Functions of Life
Super-resolution microscopes from ZEISS.
-
Product demo with features, software and best-practices
Get interesting insights about ZEISS O-INSPECT duo in our demo recording.
-
Improve Productivity and Accessibility with Award-winning Human-Centered Design
Enhance your workflow with integrated intelligence.
-
Italian pharmaceutical company buys rights to immunotherapy from Sanofi
Italy's Recordati buys the rights to a treatment for the rare autoimmune disease cold agglutinin disease (CAD).
-
Norway rejects national life science strategy – sees no need
The Norwegian Arbeiderpartiet rejects a proposal that Norway should develop its own life science strategy.
-
AstraZeneca to use American AI platform for cancer trials
In a collaboration AstraZeneca will use an AI model from Israeli-American biotech Immunai to streamline its clinical trials in cancer.
-
Compact and leak-tight powerhouse
Media-separated solenoid valve VYKA from Festo is virtually leak-free
-
Her company is developing a new tablet form obesity drug
Obesity and diabetes are the primary targets of a new tablet treatment under development by Malmö-based Pila Pharma. The company’s ambition is to take on the bi...
BREAKING